Bausch Health Completes US$63 Million Durect Acquisition, Adds Breakthrough Hepatitis Therapy to Pipeline

Published 1 month ago Positive
Bausch Health Completes US$63 Million Durect Acquisition, Adds Breakthrough Hepatitis Therapy to Pipeline
Auto

Related Stocks

BHC.TO Bausch Health C... BVF.BE Bausch Health C... BVF.MU Bausch Health C...
Bausch Health Companies (BHC.TO) Thursday said it completed its acquisition of Durect for US$1.75 pe

PREMIUM

Upgrade to read this MT Newswires article and get so much more.

A Silver or Gold subscription plan is required to access premium news articles.

Upgrade

Already have a subscription? Sign in

More News

LANTHEUS DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important November 10 Deadline in Securities Class Action – LNTH

45 minutes ago Positive

The Bahamas’ Deputy Prime Minister I. Chester Cooper Assumes Vice-Presidency of the United Nations World Tourism Organization General Assembly

55 minutes ago Positive

Valuation worries, record-long government shutdown hang over markets: What to watch this week

1 hour ago Positive

China’s earnings season is underway. Here's who’s benefiting from AI

1 hour ago Positive

Government shutdown length odds top 50 days for first time

1 hour ago Positive